现有主要疗法如外用米诺地尔与口服非那雄胺存在心悸或性欲减退等副作用，而植发手术费用高昂且非人人适用。新型候选药物包含Cosmo直接作用于毛囊的外用药物clascoterone、Veradermics开发的口服米诺地尔锭剂，以及Absci运用AI设计的注射候选药物ABS-201，各家疗法均展现庞大市场潜力。
分析师普遍看好落发治疗市场能容纳多家赢家，并视其为巨大的自费消费金矿。尽管新药研发面临高风险，且脱发问题缺乏医疗保险给付而需完全由消费者自费承担，但业界仍看好安全且便利的全新疗法将解锁庞大的全球潜在市场价值。
Following the massive success of weight-loss drugs, pharmaceutical developers and investors are turning their focus toward treatments for pattern hair loss. With tens of millions affected in the US and no newly approved medications since the late 1990s, companies like Veradermics, Absci, and Cosmo have seen substantial stock surges driven by the promise of novel therapies.
Current standard treatments such as topical minoxidil and prescription finasteride carry debilitating side effects like heart palpitations and reduced libido, while hair transplants remain expensive and inaccessible to many. Novel candidates—including Cosmo's topical clascoterone, Veradermics's oral minoxidil tablet, and Absci's AI-designed injectable ABS-201—aim to offer more effective and convenient alternatives.
Wall Street analysts view the hair-loss space as an untapped goldmine with room for multiple winners, driven by strong consumer willingness to pay out-of-pocket. Although drug development carries substantial risks and baldness treatments are unlikely to receive insurance coverage, experts believe safe and user-friendly therapies will unlock a massive global market.